ESMO Guidelines for Cutaneous
Melanoma Management Test
Questions and Answers
What were the HR for death and progression of disease in the CheckMate 066 trial? -
Answer-HR for death was 0.42 and HR for death or progression was 0.43.
What did the CheckMate 067 trial demonstrate about nivolumab compared to
ipilimumab? - Answer-Nivolumab had an HR for death of 0.63 after a minimum follow-up
of 10 years.
What was the HR for death for pembrolizumab compared to ipilimumab in the
KEYNOTE-006 trial? - Answer-The HR for death was 0.71.
What is the current standard of care (SoC) for first-line treatment of melanoma? -
Answer-PD-1 blockade is the SoC option for all patients, regardless of BRAF status.
What was the outcome of adding ipilimumab to nivolumab in the CheckMate 067 trial? -
Answer-It resulted in higher response rates and longer response durations.
What were the median OS months for nivolumab-ipilimumab, nivolumab-only, and
ipilimumab-only groups? - Answer-71.9, 36.9, and 19.9 months, respectively.
What were the median duration of response (DoR) months for nivolumab-ipilimumab,
nivolumab-only, and ipilimumab-only groups? - Answer-NR (>120 months), 103.2
months, and 19.2 months, respectively.
What percentage of patients experienced grade 3-4 AEs in the nivolumab-ipilimumab
group? - Answer-55.0%.
What should be considered when selecting first-line treatment for melanoma? - Answer-
The strategy used in the neoadjuvant and/or adjuvant setting.
What does EFS stand for in the context of melanoma treatment discussions? - Answer-
Event-Free Survival.
What does DMFS stand for in the context of melanoma treatment discussions? -
Answer-Distant Metastasis-Free Survival.
,What does RFS stand for in the context of melanoma treatment discussions? - Answer-
Recurrence-Free Survival.
What is the significance of the proposed algorithms in the management of melanoma? -
Answer-They guide treatment based on prior adjuvant treatment received.
What is the role of clinical trials in the treatment of unresectable melanoma? - Answer-
They are prioritized to address unanswered questions and resistance challenges.
What is the importance of the CheckMate 067 trial in melanoma treatment? - Answer-It
assessed the benefit of combining nivolumab with ipilimumab.
What is the implication of having no mature OS data in treatment discussions? -
Answer-It indicates uncertainty in overall survival benefits.
What does BM stand for in the context of melanoma? - Answer-Brain metastasis.
What is the role of BRAFi in melanoma treatment? - Answer-BRAF inhibitor used for
targeting BRAF V600 mutations.
What does ChT refer to in melanoma therapy? - Answer-Chemotherapy.
What is ctDNA? - Answer-Circulating tumour DNA, used for mutation detection when
tissue is unavailable.
What does EMA stand for? - Answer-European Medicines Agency.
What does ESCAT represent? - Answer-ESMO Scale for Clinical Actionability of
molecular Targets.
What is the purpose of ESMO? - Answer-European Society for Medical Oncology,
focused on improving cancer care.
What does FDA stand for? - Answer-Food and Drug Administration.
What is the function of an ICI in melanoma treatment? - Answer-Immune checkpoint
inhibitor that enhances the immune response against cancer.
What does LDH indicate in melanoma patients? - Answer-Lactate dehydrogenase, often
elevated in aggressive disease.
What does M signify in the context of melanoma? - Answer-Metastasis.
What is the MCBS? - Answer-ESMO-Magnitude of Clinical Benefit Scale, used to
evaluate treatment benefits.
,What is a MEKi? - Answer-MEK inhibitor, used in targeted therapy for melanoma.
What does NGS stand for? - Answer-Next-generation sequencing, a method for
analyzing genetic alterations.
What are PD-1 and PD-L1? - Answer-PD-1 is a programmed cell death protein 1, and
PD-L1 is its ligand, both involved in immune regulation.
What does PS refer to in clinical assessments? - Answer-Performance status, indicating
a patient's ability to perform daily activities.
What is RT in the context of melanoma treatment? - Answer-Radiotherapy.
What are TILs? - Answer-Tumour-infiltrating lymphocytes, a type of immune cell found
in tumors.
What is T-VEC? - Answer-Talimegene laherparepvec, an oncolytic virus therapy for
melanoma.
What is the significance of the ESCAT score? - Answer-It assesses the clinical
actionability of molecular targets in cancer therapy.
What are the immediate contraindications for ICI therapy? - Answer-Rapid progression,
elevated LDH levels, comorbidities, and symptoms precluding ICI use.
What is the recommendation for patients with symptomatic extracranial disease? -
Answer-Consider palliative resection, RT, and/or T-VEC, along with supportive care.
What is the status of induction targeted therapy followed by anti-PD-1 therapy? -
Answer-Not EMA or FDA approved.
What is the optimal duration of induction targeted therapy? - Answer-Currently
unknown.
What were the two treatment arms compared in the initial trial? - Answer-Arm A
received nivolumab/ipilimumab, and arm B received dabrafenib/metmetinib.
What treatment did patients in arm A receive upon disease progression? - Answer-
Patients in arm A received dabrafenib/metmetinib (arm C).
What was the median duration of response (DoR) for arm A compared to arm B? -
Answer-The median DoR was significantly longer for arm A (NR) than for arm B (12.7
months, P < 0.001).
What was the trend in progression-free survival (PFS) between arm A and arm B? -
Answer-The PFS showed a trend in favor of arm A (log-rank P = 0.054).
, What were the 2-year overall survival (OS) rates for arms A and B? - Answer-The 2-
year OS rate for arm A was 71.8%, while for arm B it was 51.5% (log-rank P = 0.010).
What percentage of patients who had disease progression in arms A or B were enrolled
into arms C or D? - Answer-Only about 50% of patients who had disease progression
were enrolled into arms C or D.
What was the grade 3 toxicity rate in arms A and B? - Answer-Grade 3 toxicity was 60%
in arm A and 52% in arm B.
What was the median PFS reported for relatlimab/nivolumab in the RELATIVITY-047
trial? - Answer-The median PFS was 10.1 months for relatlimab/nivolumab.
How did the 12-month PFS rates compare between relatlimab/nivolumab and
nivolumab? - Answer-The 12-month PFS rate was 47.7% for relatlimab/nivolumab
versus 36% for nivolumab.
What were the grade 3/4 treatment-related adverse events (TRAEs) in the
relatlimab/nivolumab group compared to nivolumab? - Answer-Grade 3/4 TRAEs
occurred in 18.9% of the relatlimab/nivolumab group versus 9.7% in the nivolumab
group.
What was the hazard ratio (HR) for PFS in patients with PD-L1 expression of <1% using
relatlimab/nivolumab? - Answer-The HR for PFS was 0.68 (95% CI 0.53-0.86).
What was the EMA's approval regarding relatlimab/nivolumab? - Answer-In July 2022,
the EMA approved relatlimab/nivolumab for first-line treatment of adults and
adolescents (≥12 years) with advanced melanoma and PD-L1 expression of <1%.
What was the outcome of the LEAP-003 trial involving pembrolizumab/lenvatinib? -
Answer-Despite significant improvement in PFS in early analysis, there was no OS
benefit, leading to trial discontinuation.
What factors should treatment decisions for melanoma be tailored based on? - Answer-
Treatment decisions should consider prior therapy, timing of recurrence, resectability
status, suitability for ICI therapy, and PD-L1 status.
What was the design of the SECOMBIT trial? - Answer-The SECOMBIT trial was a
three-arm, non-comparative phase II trial for previously untreated metastatic BRAF
V600-mutated melanoma.
What were the treatment arms in the SECOMBIT trial? - Answer-Arm A:
encorafenib/binimetinib followed by ipilimumab/nivolumab; Arm B: ipilimumab/nivolumab
followed by encorafenib/binimetinib; Arm C: encorafenib/binimetinib for 8 weeks
followed by ipilimumab/nivolumab.
Melanoma Management Test
Questions and Answers
What were the HR for death and progression of disease in the CheckMate 066 trial? -
Answer-HR for death was 0.42 and HR for death or progression was 0.43.
What did the CheckMate 067 trial demonstrate about nivolumab compared to
ipilimumab? - Answer-Nivolumab had an HR for death of 0.63 after a minimum follow-up
of 10 years.
What was the HR for death for pembrolizumab compared to ipilimumab in the
KEYNOTE-006 trial? - Answer-The HR for death was 0.71.
What is the current standard of care (SoC) for first-line treatment of melanoma? -
Answer-PD-1 blockade is the SoC option for all patients, regardless of BRAF status.
What was the outcome of adding ipilimumab to nivolumab in the CheckMate 067 trial? -
Answer-It resulted in higher response rates and longer response durations.
What were the median OS months for nivolumab-ipilimumab, nivolumab-only, and
ipilimumab-only groups? - Answer-71.9, 36.9, and 19.9 months, respectively.
What were the median duration of response (DoR) months for nivolumab-ipilimumab,
nivolumab-only, and ipilimumab-only groups? - Answer-NR (>120 months), 103.2
months, and 19.2 months, respectively.
What percentage of patients experienced grade 3-4 AEs in the nivolumab-ipilimumab
group? - Answer-55.0%.
What should be considered when selecting first-line treatment for melanoma? - Answer-
The strategy used in the neoadjuvant and/or adjuvant setting.
What does EFS stand for in the context of melanoma treatment discussions? - Answer-
Event-Free Survival.
What does DMFS stand for in the context of melanoma treatment discussions? -
Answer-Distant Metastasis-Free Survival.
,What does RFS stand for in the context of melanoma treatment discussions? - Answer-
Recurrence-Free Survival.
What is the significance of the proposed algorithms in the management of melanoma? -
Answer-They guide treatment based on prior adjuvant treatment received.
What is the role of clinical trials in the treatment of unresectable melanoma? - Answer-
They are prioritized to address unanswered questions and resistance challenges.
What is the importance of the CheckMate 067 trial in melanoma treatment? - Answer-It
assessed the benefit of combining nivolumab with ipilimumab.
What is the implication of having no mature OS data in treatment discussions? -
Answer-It indicates uncertainty in overall survival benefits.
What does BM stand for in the context of melanoma? - Answer-Brain metastasis.
What is the role of BRAFi in melanoma treatment? - Answer-BRAF inhibitor used for
targeting BRAF V600 mutations.
What does ChT refer to in melanoma therapy? - Answer-Chemotherapy.
What is ctDNA? - Answer-Circulating tumour DNA, used for mutation detection when
tissue is unavailable.
What does EMA stand for? - Answer-European Medicines Agency.
What does ESCAT represent? - Answer-ESMO Scale for Clinical Actionability of
molecular Targets.
What is the purpose of ESMO? - Answer-European Society for Medical Oncology,
focused on improving cancer care.
What does FDA stand for? - Answer-Food and Drug Administration.
What is the function of an ICI in melanoma treatment? - Answer-Immune checkpoint
inhibitor that enhances the immune response against cancer.
What does LDH indicate in melanoma patients? - Answer-Lactate dehydrogenase, often
elevated in aggressive disease.
What does M signify in the context of melanoma? - Answer-Metastasis.
What is the MCBS? - Answer-ESMO-Magnitude of Clinical Benefit Scale, used to
evaluate treatment benefits.
,What is a MEKi? - Answer-MEK inhibitor, used in targeted therapy for melanoma.
What does NGS stand for? - Answer-Next-generation sequencing, a method for
analyzing genetic alterations.
What are PD-1 and PD-L1? - Answer-PD-1 is a programmed cell death protein 1, and
PD-L1 is its ligand, both involved in immune regulation.
What does PS refer to in clinical assessments? - Answer-Performance status, indicating
a patient's ability to perform daily activities.
What is RT in the context of melanoma treatment? - Answer-Radiotherapy.
What are TILs? - Answer-Tumour-infiltrating lymphocytes, a type of immune cell found
in tumors.
What is T-VEC? - Answer-Talimegene laherparepvec, an oncolytic virus therapy for
melanoma.
What is the significance of the ESCAT score? - Answer-It assesses the clinical
actionability of molecular targets in cancer therapy.
What are the immediate contraindications for ICI therapy? - Answer-Rapid progression,
elevated LDH levels, comorbidities, and symptoms precluding ICI use.
What is the recommendation for patients with symptomatic extracranial disease? -
Answer-Consider palliative resection, RT, and/or T-VEC, along with supportive care.
What is the status of induction targeted therapy followed by anti-PD-1 therapy? -
Answer-Not EMA or FDA approved.
What is the optimal duration of induction targeted therapy? - Answer-Currently
unknown.
What were the two treatment arms compared in the initial trial? - Answer-Arm A
received nivolumab/ipilimumab, and arm B received dabrafenib/metmetinib.
What treatment did patients in arm A receive upon disease progression? - Answer-
Patients in arm A received dabrafenib/metmetinib (arm C).
What was the median duration of response (DoR) for arm A compared to arm B? -
Answer-The median DoR was significantly longer for arm A (NR) than for arm B (12.7
months, P < 0.001).
What was the trend in progression-free survival (PFS) between arm A and arm B? -
Answer-The PFS showed a trend in favor of arm A (log-rank P = 0.054).
, What were the 2-year overall survival (OS) rates for arms A and B? - Answer-The 2-
year OS rate for arm A was 71.8%, while for arm B it was 51.5% (log-rank P = 0.010).
What percentage of patients who had disease progression in arms A or B were enrolled
into arms C or D? - Answer-Only about 50% of patients who had disease progression
were enrolled into arms C or D.
What was the grade 3 toxicity rate in arms A and B? - Answer-Grade 3 toxicity was 60%
in arm A and 52% in arm B.
What was the median PFS reported for relatlimab/nivolumab in the RELATIVITY-047
trial? - Answer-The median PFS was 10.1 months for relatlimab/nivolumab.
How did the 12-month PFS rates compare between relatlimab/nivolumab and
nivolumab? - Answer-The 12-month PFS rate was 47.7% for relatlimab/nivolumab
versus 36% for nivolumab.
What were the grade 3/4 treatment-related adverse events (TRAEs) in the
relatlimab/nivolumab group compared to nivolumab? - Answer-Grade 3/4 TRAEs
occurred in 18.9% of the relatlimab/nivolumab group versus 9.7% in the nivolumab
group.
What was the hazard ratio (HR) for PFS in patients with PD-L1 expression of <1% using
relatlimab/nivolumab? - Answer-The HR for PFS was 0.68 (95% CI 0.53-0.86).
What was the EMA's approval regarding relatlimab/nivolumab? - Answer-In July 2022,
the EMA approved relatlimab/nivolumab for first-line treatment of adults and
adolescents (≥12 years) with advanced melanoma and PD-L1 expression of <1%.
What was the outcome of the LEAP-003 trial involving pembrolizumab/lenvatinib? -
Answer-Despite significant improvement in PFS in early analysis, there was no OS
benefit, leading to trial discontinuation.
What factors should treatment decisions for melanoma be tailored based on? - Answer-
Treatment decisions should consider prior therapy, timing of recurrence, resectability
status, suitability for ICI therapy, and PD-L1 status.
What was the design of the SECOMBIT trial? - Answer-The SECOMBIT trial was a
three-arm, non-comparative phase II trial for previously untreated metastatic BRAF
V600-mutated melanoma.
What were the treatment arms in the SECOMBIT trial? - Answer-Arm A:
encorafenib/binimetinib followed by ipilimumab/nivolumab; Arm B: ipilimumab/nivolumab
followed by encorafenib/binimetinib; Arm C: encorafenib/binimetinib for 8 weeks
followed by ipilimumab/nivolumab.
